key: cord-0929178-yuh2joa8
authors: Akbil, B.; Meyer, T.; Stubbemann, P.; Thibeault, C.; Staudacher, O.; Niemeyer, D.; Jansen, J.; Muehlemann, B.; Doehn, J.-M.; Tabeling, C.; Nusshag, C.; Hirzel, C.; Soekler Sanchez, D.; Nieters, A.; Lother, A.; Duerschmied, D.; Schallner, N.; Lieberum, J. N.; August, D.; Rieg, S.; Falcone, V.; Hengel, H.; Koelsch, U.; Unterwalder, N.; Huebner, R.-H.; Jones, T. C.; Suttorp, N.; Drosten, C.; Warnatz, K.; Spinetti, T.; Schefold, J. C.; Doerner, T.; Sander, L.; Corman, V. M.; Merle, U.; Kurth, F.; von Bernuth, H.; Meisel, C.; Goffinet, C.
title: Early and rapid identification of COVID-19 patients with neutralizing type I-interferon auto-antibodies by an easily implementable algorithm
date: 2021-11-15
journal: nan
DOI: 10.1101/2021.11.12.21266249
sha: a070acae26efd67d627d1da80a638fa8ab9ff7ec
doc_id: 929178
cord_uid: yuh2joa8

Purpose Six-19% of critically ill COVID-19 patients display circulating auto-antibodies against type I interferons (IFN-AABs). Here, we establish a clinically applicable strategy for early identification of IFN-AAB-positive patients for potential subsequent clinical interventions. Methods We analysed sera of 430 COVID-19 patients with severe and critical disease from four hospitals for presence of IFN-AABs by ELISA. Binding specificity and neutralizing activity were evaluated via competition assay and virus-infection-based neutralization assay. We defined clinical parameters associated with IFN-AAB positivity. In a subgroup of critically ill patients, we analyzed effects of therapeutic plasma exchange (TPE) on the levels of IFN-AABs, SARS-CoV-2 antibodies and clinical outcome. Results The prevalence of neutralizing AABs to IFN- and IFN-{omega} in COVID-19 patients was 4.2% (18/430), while being undetectable in an uninfected control cohort. Neutralizing IFN-AABs were detectable exclusively in critically affected, predominantly male (83%) patients (7.6% IFN- and 4.6% IFN-{omega} in 207 patients with critical COVID-19). IFN-AABs were present early post-symptom onset and at the peak of disease. Fever and oxygen requirement at hospital admission co-presented with neutralizing IFN-AAB positivity. IFN-AABs were associated with higher mortality (92.3% versus 19.1 % in patients without IFN-AABs). TPE reduced levels of IFN-AABs in three of five patients and may increase survival of IFN-AAB-positive patients compared to those not undergoing TPE. Conclusion IFN-AABs may serve as early biomarker for development of severe COVID-19. We propose to implement routine screening of hospitalized COVID-19 patients according to our algorithm for rapid identification of patients with IFN-AABs who most likely benefit from specific therapies.

IFN-AABs may serve as early biomarker for development of severe COVID-19. We propose 115 to implement routine screening of hospitalized COVID-19 patients according to our algorithm 116 for rapid identification of patients with IFN-AABs who most likely benefit from specific 117 therapies. 118 119 3-5 KEYWORDS 120 COVID-19, SARS-CoV-2, type I interferon, autoantibodies 121 122 . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted November 15, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 

Since its first detection in Wuhan, China, in 2019, Severe-acute-respiratory syndrome 124

Coronavirus 2 (SARS-CoV-2) has placed an unprecedented burden on health care systems 125 worldwide. The clinical spectrum of the associated disease, COVID-19, ranges from 126 asymptomatic infection to severe disease with hypoxemia, acute respiratory distress 127 syndrome (ARDS), multiorgan failure, and death (Pfortmueller et al. 2021 ). Approximately 128 35% of patients remain asymptomatic, 55% develop upper respiratory tract infections, 129 whereas 15% develop severe pneumonia (defined as SpO2 < 90% at room air) and 5% 130 critical pneumonia (defined as Acute Respiratory Distress Syndrome (ARDS), requiring 131 mechanical ventilation or extra-corporeal membrane (ECMO) (Sah et al. 2021) . 132

Scores containing clinical and laboratory parameters support risk stratification and 133 resource allocation in clinical practice worldwide ; "Information on Prevention and Research" n.d.) . Demographic and clinical risk factors for a 135 severe disease course include advanced age, male sex, and pre-existing comorbidities 136 . Moreover, genetic polymorphisms are associated with progression 137 to severe disease (COVID-19 Host Genetics Initiative 2021). Cell-intrinsic innate viral 138 sensors and antiviral cytokines, including type I and type III interferons (IFNs), orchestrate 139 the control of SARS-CoV-2 infection . Inherited mutations of genes 140 involved in IFN induction and signalling and circulating auto-antibodies (AABs) that 141 neutralize type I IFNs have been found to predispose infected individuals to severe 19 , presumably by contributing to an ineffective 143 immune response with delayed or abolished type I IFN signaling. Neutralizing type I AABs are present in 6-17% of hospitalized COVID-19 patients with severe pneumonia 145 Koning et al. 2021; ) and 11-19% in critically ill 146 COVID-19 patients Goncalves et al. 2021), 147 greatly exceeding estimated prevalences of around 0.33% in uninfected 148 individuals. Intriguingly, while neutralizing IFN-AABs in patients with autoimmune 149 polyendocrine syndrome type 1 (APS-1) can associate with a severe course of SARS-CoV-2 150 . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted November 15, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 infection 151 Lemarquis et al. 2021) , their mere presence does not inevitably lead to severe disease 152 . A recent global multi-cohort study reports prevalence of neutralizing 153 IFN-AABs in 4% of uninfected individuals over 70 years of age, suggesting that IFN-AABs 154 may pre-exist in some individuals that develop a critical course of COVID-19 (Bastard et al. 155 2021) . Thus, we reasoned that IFN-AABs may serve as biomarkers that could, in conjunction 156 with other clinical parameters, help to predict risk for developing severe COVID-19 and to 157 stratify patients for specific therapies. 158

Specific therapies may comprise the administration of recombinant IFN-β or 159 therapeutic plasma exchange (TPE). However, the clinical benefit of TPE and other 160 approaches remains to be defined and requires studies involving large numbers of patients. 161

With IFN-AABs present in up to 18% of deceased COVID-19 patients (Bastard et al. 2021) 162 and given the limited therapeutic options for severely affected COVID-19 patients, testing 163 specific therapeutic approaches is of high urgency, yet clinically implementable strategies for 164 rapid and early identification of IFN-AAB-positive patients upfront are missing. 165 . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted November 15, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 University Hospital, Germany ) and supplementary methods) were 178 retrospectively selected. All TPE procedures were performed in accordance with the German 179 Medical Devices Act ("Medizinproduktegesetz"). Healthy controls were recruited from a study 180 on SARS-CoV-2 exposition in health care workers (HC cohort). Samples from APS-1 181 patients were obtained from a published study ) and published values are 182 shown here for reference. All studies were conducted according to the Declaration of 183

Helsinki and Good Clinical Practice principles (ICH 1996) . 184 185 Detection of IFN-AABs by reverse ELISA 186 IFN-AABs were detected using an electrochemiluminescence immunoassay (ECLIA)-187 platform (MSD, Rockville, U.S.), as described recently 

. CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint w  h  e  n  p  r  e  i  n  c  u  b  a  t  i  o  n  w  i  t  h  t  h  e  h  i  g  h  e  s  t  c  o  n  c  e  n  t  r  a  t  i  o  n  o  f  I  F  N  -α  2  o  r  I  F  N  -⍵  r  e  s  u  l  t  e  d  i  n  a  n   207   a  t  l  e  a  s  t  f  o  u  r  -f  o  l  d  r  e  d  u  c  t  i  o  n  o  f  L  S  C  i  n  c  o  m  p  a  r  i  s  o  n  t  o  a  n  a  l  y  s  i  s  o  f  t  h  e  i  d  e  n  t  i  c  a  l  s  e  r  u  m  w 

Calu-3 cells were pre-incubated with 1% human serum in the presence or absence of 200-212 400 IU/ml IFN-α2a (Roferon®-A, Roche) or 20-50 ng/ml IFN-ω (PeproTech). After 24 hours, 213 IFN and serum were removed and cells were infected with SARS-CoV-2 at MOI 0.01. Virus 214 inoculum was removed after one hour, cells were washed with PBS and 100 µl medium was 215 . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint 

We then screened sera obtained at the peak of the disease from 242 patients of cohorts A-C (CSC) and cohort D (TPEC (Meisel et 248 al. 2021) ). 249

Nonspecific binding is a common phenomenon in immunoassays for the detection of 250

AABs, and high levels of inflammatory parameters such as CRP correlate with non-specific 251 binding of (auto-)antibodies . Therefore, we probed the specificity of all 252 samples exceeding the 97.5th percentile of the IFN-AAB ELISA and 27 samples that scored 253 right below the cut-off in a competition assay (Fig. 1b) . Based on the assumption that sera 254 scoring below the cut-off did not contain IFN-AABs, we established a prevalence of specific 255 IFN--AAB of 3.2% (13/403) and of specific (4/27) or both (14.8%, 4/27) ( Fig. 1a-b) . As expected, all tested samples scoring below 258 the 97.5th percentile in the ELISA scored negative in the specificity assay with the exception 259 of one patient (B044) who scored slightly below the cut-off in the

Importantly, none of the tested sera from the HC displayed antibodies that specifically bound 261 IFN-or IFN-. 262

We next analyzed whether the presence of detectable and specifically IFN-binding AABs 265 corresponded to a functional neutralization of IFN during infection. To this end, we applied a 266 previously established assay of IFN-based inhibition of SARS-CoV-2 infection of the 267 immortalized lung cell line Calu-3 , which we consider the gold standard 268 for analysis of IFN neutralization. We tested the extent to which sera neutralize the antiviral 269 activity of type I IFNs, resulting in efficient infection despite presence of IFNs. We tested all 270 ELISA-positive sera as well as 102 ELISA-negative sera as a reference. 13 (3.2 %) and 8 271 . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted November 15, 2021. ; https://doi.org/10.1101/2021.11.12.21266249 doi: medRxiv preprint (2.0 %) of the 403 sera of the CSC specifically neutralized exogenous 272 respectively, as judged by PCR-based quantification of SARS-CoV-2 genomic RNA in the 273 supernatant and plaque assays that quantify infectivity of virus progeny ( Fig. 2a-b, Fig. S1 ). 274

In cohort D (TPEC), 5 (18.5%) and 3 (11.1%) of 27 sera neutralized IFN-and IFN-275 activity, respectively ( Fig. 2a-b, Fig. S1 ). 276

Strikingly, among competition assay-positive samples, 18 (100%) of 18, and 9 (90%) 277 of 10 sera displayed IFN-and IFN--neutralizing activity, respectively, indicating that a 278 positive result in the competition assay associates with neutralization activity with a high 279 likelihood ( Fig. 1c-d) . Conversely, a negative result in the competition assay was predictive 280 of absence of neutralization ability. Specifically, among ELISA-positive, but competition 281 assay-negative sera, 0 (0%) of 23 and 0 (0%) of 29 sera were able to neutralize IFN-and 282 IFN-, respectively. Among IFN-α AAB-ELISA-negative sera, we observed no IFN-283 neutralizing activity. Interestingly, among IFN-ω AAB-ELISA-negative sera, we identified two 284 samples that neutralized IFN-ω despite scoring negative in the IFN-ω-AAB ELISA (i.e., 285 having LSC counts below the 97.5th percentile cut-off) (Fig. 2b, d) . The pronounced ability of 286 these exact two sera to neutralize IFN-α (Fig. 2a, c) was the reason why we included them in 287 the IFN-ω test, and suggests a potential cross-reactivity of IFN-α-AAB with Merging results from all three assays ( 

We next aimed to characterize the clinical phenotype of IFN-neutralizing AAB-positive 297 COVID-19 patients in the CSC at hospital admission, and to identify discriminatory markers 298 that may serve as pre-selection criteria for their early identification and stratification. 299 . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted November 15, 2021. ; https://doi.org/10. 1101 Interestingly, there were no statistically significant differences regarding clinical baseline 300 characteristics, including demographic criteria and pre-existing comorbidities between 301 patients with and without IFN-neutralizing AABs in the CSC using univariate analyses (Table  302   1 ). Yet, of all patients with available symptom records (cohorts A and C), the proportion of 303 patients who reported fever and required supplemental oxygen therapy within 72 hours from 304 admission was higher in patients with neutralizing IFN-AABs than in those without (fever: 305 100%, 12/12 versus 62.6% (234/374), p=0.0079 and oxygen: 100% (12/12) versus 76.0% 306 (250/329), p=0.0528). 307

Furthermore, patients with IFN-AABs for which respective data were available 308 displayed higher median values of C-reactive protein (CRP), procalcitonin, lactate 309 dehydrogenase (LDH), ferritin, total leukocyte and neutrophil count, as well as neutrophil-to-310 lymphocyte ratio within the first three days of hospital admission compared to patients 311 without IFN-AABs (Fig. 3, Fig. S3 ). In addition, patients with neutralizing IFN-AABs showed 312 low levels of CD169/Siglec-1 expression on monocytes, a well-known type I IFN-response 313 marker (Fig. S4) . Interestingly, there was a tendency towards a negative correlation between 314 CRP levels and CD169/Siglec-1 within 72 hours from hospital admission. 315

In IFN-AAB-positive patients, high quantities of neutralizing IFN-α2-AABs were 317 present both soon post-symptom onset and at the peak of disease 318

Next, we evaluated the temporal dynamics of IFN-AAB levels in sera from COVID-19 319 patients soon after symptom onset as compared to the peak of the disease. Available 320 samples obtained in cohort A, and in cohort D (TPEC) prior to TPE were analyzed (Fig. 4 , 321 CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted November 15, 2021. ; https://doi.org/10.1101/2021.11.12.21266249 doi: medRxiv preprint

We next aimed to identify potential quantitative and/or qualitative differences in cytokine 330 responses, viral load and seroconversion kinetics in IFN-AAB-positive as opposed to IFN-331 AAB-negative patients. We analyzed serum cytokine levels in a subset of critical patients 332 (WHO max. 6-8) from cohort A. Patients with neutralizing IFN-AABs demonstrated 333 significantly higher levels of IFN-γ, and IFN-γ-induced protein 10 (IP-10) one to two weeks 334 PSO while monocyte chemoattractant protein-1 (MCP-1) and TNF-α concentrations were 335 similar compared to sera from patients without neutralizing IFN-AABs (Fig. S6) . However, 336 levels equalized among the two groups at three to four weeks PSO. As expected, patients 337 with IFN-AABs had undetectable serum IFN-levels. Of note, by comparing upper-338 respiratory tract swabs and sera from patients with and without IFN-AABs from all infected 339 cohorts, we failed to identify detectable differences in viral load level or decay over time (Fig. 340 S7a) and we found no evidence for a difference in duration until seroconversion PSO (Fig.  341 S7b). In conclusion, some cytokine responses were aberrantly elevated in patients with AABs within the first two weeks PSO. However, they normalized at weeks three and four, 343 and viral RNA production and time to seroconversion remained indistinguishable from 344 patients without IFN-AABs. 345

Neutralizing IFN-AAB-positive patients developed significantly higher max. WHO scores than 348 patients without neutralizing IFN-AABs (median max. WHO score 8 (IQR 8-8) vs 6 (IQR 4-7), 349 respectively; p<0.0001, Fig. 5a for the patients from the non-neutralizing group, as opposed to 7.7% (1/13) for the patients 359 of the neutralizing IFN-AAB-positive group (Fig. 5c) positive patients from the TPEC that survived in hospital was higher than of those patients 379 from the CSC who did not undergo TPE (60%, 3/5 patients from the TPEC survived versus 380 7.7%, 1/13 patients from the CSC, p=0.0412) (Fig. 6a) . 381 . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted November 15, 2021. ; https://doi.org/10. 1101 Longitudinal analysis of sera revealed that three (D011, D017, D018) out of five 382 patients responded to TPE with decreasing IFN-AAB levels below the cut-off and to a level 383 that coincided with absence of neutralizing activity. In addition, a sustained reduction of IFN-384 AAB quantities was achieved only by repetitive TPE (Fig. 5b, Fig. S8 ). In contrast to AABs, quantities of SARS-CoV-2 Spike IgG and IgA were less, if at all, affected by TPE 386 such as TPE. In the CSC cohort, the patient number needed to screen (NNS) without 397 preselection in order to identify one patient with neutralizing IFN-AAB was 31.0 (403/13). We 398 hypothesized that applying clinical pre-selection criteria which strongly co-present with the 399 neutralizing IFN-AAB positivity diminishes the NNS. Using univariate analyses, we 400 established that temperature (>38.5 °C or self-reported) before or upon hospital admission 401 and the need for supplemental oxygen within the first 72 hours after admission correlated 402 best with presence of IFN-AAB positivity in the screening assay in all hospitalized COVID-19 403 patients (fever: p=0.0079; supplemental oxygen p=0.0528). Using fever and need for 404 supplemental oxygen, the NNS was reduced to 15.6 (172/11). Selection of patients 405 exceeding the cut-off for ELISA positivity (in our cohort 97.5th percentile of the HC) for 406 further testing by competition assay would adjust the NNS in the competition assay to 1.4 407 (15/11). Therefore, in order to increase sensitivity, we propose to consider the need for 408 . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted November 15, 2021. ; https://doi.org/10.1101/2021.11.12.21266249 doi: medRxiv preprint supplemental oxygen within 72 hours after admission and fever as pre-selection criteria for 409 patients that undergo ELISA screening (Fig. 7) . 410 Sera from all patients exceeding the LSC value of 35,639 (13/13) in the screening 411 ELISA assay demonstrated neutralizing activity against IFN-α (Fig. 2c) . We therefore 412

propose to conduct the IFN neutralization assay only in case of an LSC value lower than 413 35,639, whereas patients with sera exceeding this value can be considered positive for 414 neutralizing IFN-AABs without further testing (Fig. 7) . is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted November 15, 2021. ; https://doi.org/10. 1101 We failed to identify a clear association of IFN-AABs with previously described 465 demographic parameters in our cross-sectional cohort, including male sex or advanced age 466 , probably due to the relatively limited sample size of our cohorts. de Prost et al. 492 . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted November 15, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 https://doi.org/10. .11.12.21266249 doi: medRxiv preprint 2021 ) and might efficiently remove soluble circulating Fc gamma 493 receptor-activating immune complexes (Ankerhold et al. 2021) . TPE effectively decreased 494 circulating IFN-AAB, but not SARS-CoV-2 antibody concentrations in four IFN-AAB-positive, 495 severely ill patients and in a child with APS-1 suffering from severe 496 COVID-19 . In our study, TPE reduced circulating IFN-AABs with 497 patient-specific efficiency and appeared to increase the chances of in-hospital survival, 498 underlining the rationale to initiate large-scale, adequately powered clinical trials in order to 499 corroborate the potential benefit of TPE in a general cohort of adult, critically ill COVID-19 500 patients. Interestingly, SARS-CoV-2-IgG and IgA quantities were less affected by TPE for 501 unknown reasons, which may include their rapid replenishment by highly abundant 502 plasmablasts or an extravascular-to-intravascular rebound since immunoglobulins have a 503 substantial extravascular distribution. clinical studies. Our diagnostic algorithm for their identification may support clinicians to 516 promptly identify patients carrying this additional risk factor for progression to severe disease 517 upon hospital admission. It is based on clinical preselection of patients presenting with fever 518 and need for supplemental oxygen therapy within 72 hours after admission to be further 519 screened by an ELISA-based assay for circulating IFN-AABs and an easily implementable 520 . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted November 15, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 ELISA-based validation assay which may be skipped in case of high positivity in the 521 screening assay (Fig. 7) . Screening criteria should be validated in the future in a large 522 prospective observational cohort. Ideally, methodological complex gold-standard assays can 523 be substituted by high-throughput diagnostic tests and stratification by clinical parameters, 524 facilitating clinical implementation. Our algorithm may allow identifying at-risk patients upon 525 presentation in the emergency room to be directly allocated to TPE and/or IFN-β therapy 526 within larger clinical trials, which are urgently needed to determine clinical effectiveness of 527 these targeted therapies. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted November 15, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 Practice principles (ICH 1996) . 619

The Pa-COVID-19 study was approved by the ethics committee of Charité -620

Universitätsmedizin Berlin (EA2/066/20) and is registered in the German and WHO 621 international clinical trials registry (DRKS00021688). 622

The Covimmun-study was approved by the ethics committee of Charité -623

Universitätsmedizin Berlin (EA1/068/20). 624

The study "Evaluation der humoralen und zellulären Immunantwort und der 625 thromboembolischen Komplikationen bei Infektion mit dem neuartigen Coronavirus 626 (nCoV19)" was approved by the Kantonale Ethikkommission KEK, Bern, Switzerland, Nr. 627 2020-00877 and is registered under the name "Characterizing the Immune Response and 628

Neuronal Damage in COVID-19" at http://clinicaltrials.gov (NCT04510012). 629

The three studies were approved by the ethics committee of the University of Freiburg (EK-FR 631 . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted November 15, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 FREEZE-Biobank EK-FR 383/19; EK-FR 225/20) and are registered in the German 632 and WHO international clinical trials registry (DRKS00021522 for Biomarker . 633

The Covid-Immun study was approved by the local Ethics Committee of the Medical Faculty 634 of Heidelberg (S148/2020) and is registered in the German clinical trials registry 635 (DRKS00021810). Dotted lines indicate the 97.5th percentile of the ECLIA assay LSC in sera from the HC 655 cohort. Dots indicate samples containing AABs scoring specific (red) or unspecific (blue) for 656 IFN-α2 and IFN-ω binding in the competition assay (see b), respectively. The prevalence of 657 sera with specifically binding type I IFN-AABs in each cohort is given in percent. 658 . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted November 15, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 (b) Specificity of the ECLIA assay signal for IFN-α2-and IFN-ω-AABs was tested in an 659 competition assay by preincubation of sera with increasing concentrations of unlabeled IFN-660 α 2 and IFN-ω protein (0 -2.5 µg/ml) before analysis. Samples showing a decrease in assay 661 signal by at least 75% in the presence of the highest competitor concentration were defined 662 as specific for type I IFN antibody reactivity and are indicated with red lines (IFN-α2 n=18 Values of C-reactive protein (CRP), procalcitonin, ferritin, lactate dehydrogenase (LDH), 683 absolute leukocyte and neutrophil count and neutrophil-to-lymphocyte ratio (NLR) of patients 684 with (N=5-6) and without neutralizing IFN-AABs (N=200-265) from the cross-sectional cohort 685 . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint neutralizing TPEC). Statistical testing was performed using a log-rank test. Neutralizing CSC 713 . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. AABs is reduced to 1.4 (15/11) (4). For patients with high-titer IFN-AABs (light signal count > 732 35.639), the competition assay can be omitted. For patients highly positive in the IFN-AAB 733 ELISA and those with specific results in the competition assay, we propose to consider 734 therapeutic plasma exchange within clinical studies (5). 735 736 . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

Length of hospital stay in days (Median, IQR, available n)

Neutralizing Type-I Interferon Autoantibodies Are Associated with Delayed Viral Clearance and Intensive Care Unit Admission in Patients with COVID-19

Circulating Multimeric Immune Complexes Drive Immunopathology in COVID-19

Preexisting Autoantibodies to Type I IFNs Underlie Critical COVID-19 Pneumonia in Patients with APS-1

Autoantibodies against Type I IFNs in Patients with Life-Threatening COVID-19

A COVID-19 Pneumonia Case Report of Autoimmune Polyendocrine Syndrome Type 1 in Lombardy, Italy: Letter to the Editor

Autoimmune Polyendocrinopathy-Candidiasis-Ectodermal Dystrophy in Two Siblings: Same Mutations but Very Different Phenotypes

Detection of 2019 Novel Coronavirus (2019-nCoV) by Real-Time RT-PCR

Mapping the Human Genetic Architecture of COVID-19

Plasma Exchange: An Effective Rescue Therapy in Critically Ill Patients With Coronavirus Disease 2019 Infection

SARS-CoV-2 Spike Protein-Directed Monoclonal Antibodies May Ameliorate COVID-19 Complications in APECED Patients

Antibodies against Type I Interferon: Detection and Association with Severe Clinical Outcome in COVID-19 Patients

Non-Specific Binding in Solid Phase Immunoassays for Autoantibodies Correlates with Inflammation Markers

Estimating Infectiousness throughout SARS-CoV-2 Infection Course

Type I and III Interferon Responses in SARS-CoV-2 Infection

Risk Stratification of Patients Admitted to Hospital with Covid-19 Using the ISARIC WHO Clinical Characterisation Protocol: Development and Validation of the 4C Mortality Score

Autoantibodies against Type I Interferons Are Associated with Multi-Organ Failure in COVID-19 Patients

Studying the Pathophysiology of Coronavirus Disease 2019: A Protocol for the Berlin Prospective COVID-19 Patient Cohort (Pa-COVID-19)

Severe COVID-19 in an APS1 Patient with Interferon Autoantibodies Treated with Plasmapheresis

Mild COVID-19 despite Autoantibodies to Type I IFNs in Autoimmune-Polyendocrine-Syndrome Type 1 (APS-1)

AIRE-Deficient Patients Harbor Unique High-Affinity Disease-Ameliorating Autoantibodies

Plasma Exchange in Patients With Severe Coronavirus Disease 2019: A Single-Center Experience

Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibody Responses in Coronavirus Disease Patients

COVID-19-Associated Acute Respiratory Distress Syndrome (CARDS): Current Knowledge on Pathophysiology and ICU Treatment -A Narrative Review

Plasma Exchange to Rescue Patients with Autoantibodies Against Type I Interferons and Life-Threatening COVID-19 Pneumonia

Asymptomatic SARS-CoV-2 Infection: A Systematic Review and Meta-Analysis

False-Positive Results in ELISA-Based Anti FVIII Antibody Assay May Occur with Lupus Anticoagulant and Phospholipid Antibodies

Delayed Antibody and T-Cell Response to BNT162b2 Vaccination in the Elderly

Reduced Monocytic Human Leukocyte Antigen-DR Expression Indicates Immunosuppression in Critically Ill COVID-19 Patients

SIGLEC1 (CD169) Is a Sensitive Biomarker for the Deterioration of the Clinical Course in Childhood Systemic Lupus Erythematosus

Neutralizing Autoantibodies to Type I IFNs in >10% of Patients with Severe COVID-19 Pneumonia Hospitalized in Madrid, Spain

Repurposed Antiviral Drugs for Covid-19 -Interim WHO Solidarity Trial Results

Type I Interferon Autoantibodies Are Associated with Systemic Immune Alterations in Patients with COVID-19

Factors Associated with COVID-19-Related Death Using OpenSAFELY

Virological Assessment of Hospitalized Patients with COVID-2019

Inborn Errors of Type I IFN Immunity in Patients with Life-Threatening COVID-19

Neutralizing Type-I Interferon Autoantibodies Are Associated with Delayed Viral Clearance and Intensive Care Unit Admission in Patients with COVID-19

Preexisting Autoantibodies to Type I IFNs Underlie Critical COVID-19 Pneumonia in Patients with APS-1

Autoantibodies against Type I IFNs in Patients with Life-Threatening COVID-19

A COVID-19 Pneumonia Case Report of Autoimmune Polyendocrine Syndrome Type 1 in Lombardy, Italy: Letter to the Editor

Autoimmune Polyendocrinopathy-Candidiasis-Ectodermal Dystrophy in Two Siblings: Same Mutations but Very Different Phenotypes

Detection of 2019 Novel Coronavirus (2019-nCoV) by Real-Time RT-PCR

Mapping the Human Genetic Architecture of COVID-19

Plasma Exchange: An Effective Rescue Therapy in Critically Ill Patients With Coronavirus Disease 2019 Infection

SARS-CoV-2 Spike Protein-Directed Monoclonal Antibodies May Ameliorate COVID-19 Complications in APECED Patients

Antibodies against Type I Interferon: Detection and Association with Severe Clinical Outcome in COVID-19 Patients

Non-Specific Binding in Solid Phase Immunoassays for Autoantibodies Correlates with Inflammation Markers

Estimating Infectiousness throughout SARS-CoV-2 Infection Course

Type I and III Interferon Responses in SARS-CoV-2 Infection

Risk Stratification of Patients Admitted to Hospital with Covid-19 Using the ISARIC WHO Clinical Characterisation Protocol: Development and Validation of the 4C Mortality Score

Autoantibodies against Type I Interferons Are Associated with Multi-Organ Failure in COVID-19 Patients

Severe COVID-19 in an APS1 Patient with Interferon Autoantibodies Treated with Plasmapheresis

Mild COVID-19 despite Autoantibodies to Type I IFNs in Autoimmune-Polyendocrine-Syndrome Type 1 (APS-1)

AIRE-Deficient Patients Harbor Unique High-Affinity Disease-Ameliorating Autoantibodies

Plasma Exchange in Patients With Severe Coronavirus Disease 2019: A Single-Center Experience

Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibody Responses in Coronavirus Disease Patients

Plasma Exchange to Rescue Patients with Autoantibodies Against Type I Interferons and Life-Threatening COVID-19 Pneumonia

False-Positive Results in ELISA-Based Anti FVIII Antibody Assay May Occur with Lupus Anticoagulant and Phospholipid Antibodies

Delayed Antibody and T-Cell Response to BNT162b2 Vaccination in the Elderly

Reduced Monocytic Human Leukocyte Antigen-DR Expression Indicates Immunosuppression in Critically Ill COVID-19 Patients

SIGLEC1 (CD169) Is a Sensitive Biomarker for the Deterioration of the Clinical Course in Childhood Systemic Lupus Erythematosus

Neutralizing Autoantibodies to Type I IFNs in >10% of Patients with Severe COVID-19 Pneumonia Hospitalized in Madrid, Spain

Repurposed Antiviral Drugs for Covid-19 -Interim WHO Solidarity Trial Results

Type I Interferon Autoantibodies Are Associated with Systemic Immune Alterations in Patients with COVID-19

Factors Associated with COVID-19-Related Death Using OpenSAFELY

Virological Assessment of Hospitalized Patients with COVID-2019

Inborn Errors of Type I IFN Immunity in Patients with Life-Threatening COVID-19